Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials.

Rebecca Svanberg Teglgaard Hanne Vibeke Hansen Marquart Hans Jakob Hartling Jakob Thaning Bay Caspar da Cunha-Bang Christian Brieghel Tereza Faitová Lisbeth Enggaard Arnon P Kater Mark-David Levin Sabina Kersting Sisse Rye Ostrowski Carsten Utoft Niemann

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Innate immune impairment and infection susceptibility in CLL patients were restored in parallel during targeted therapy. Thus, targeted treatment may reduce the risk of infections in CLL, as currently under investigation in the PreVent-ACaLL phase 2 trial of acalabrutinib+venetoclax for high risk CLL (NCT03868722).

Keyphrases

chronic lymphocytic leukemia
innate immune
clinical trial
newly diagnosed
end stage renal disease
ejection fraction
prognostic factors
randomized controlled trial
cancer therapy
combination therapy
open label
phase ii